Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Prostate Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(421)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
darolutamide
Sensitive: A1 - Approval
Bayer Press Release - 4 days (New B)
darolutamide
Sensitive
:
A1
Bayer Press Release - 4d
darolutamide
Sensitive: A1 - Approval
Bayer Press Release - 4 days
darolutamide
Sensitive
:
A1
Bayer Press Release - 4 days - (New B)
CHEK2 mutation
Prostate Cancer
CHEK2 mutation
Prostate Cancer
pembrolizumab
Sensitive: C4 – Case Studies
BMJ Case Rep - 1 week (New C4)
pembrolizumab
Sensitive
:
C4
BMJ Case Rep - 1wk
pembrolizumab
Sensitive: C4 – Case Studies
BMJ Case Rep - 1 week
pembrolizumab
Sensitive
:
C4
BMJ Case Rep - 1 week - (New C4)
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
apalutamide
Sensitive: A1 - Approval
apalutamide
Sensitive
:
A1
apalutamide
Sensitive: A1 - Approval
apalutamide
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
histrelin acetate
Sensitive: A1 - Approval
histrelin acetate
Sensitive
:
A1
histrelin acetate
Sensitive: A1 - Approval
histrelin acetate
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
cabazitaxel
Sensitive: A1 - Approval
cabazitaxel
Sensitive
:
A1
cabazitaxel
Sensitive: A1 - Approval
cabazitaxel
Sensitive
:
A1
BRCA2 mutation
Prostate Cancer
BRCA2 mutation
Prostate Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA1 mutation
Prostate Cancer
BRCA1 mutation
Prostate Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
enzalutamide capsule
Sensitive: A1 - Approval
enzalutamide capsule
Sensitive
:
A1
enzalutamide capsule
Sensitive: A1 - Approval
enzalutamide capsule
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
relugolix
Sensitive: A1 - Approval
relugolix
Sensitive
:
A1
relugolix
Sensitive: A1 - Approval
relugolix
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
docetaxel + prednisone
Sensitive: A1 - Approval
docetaxel + prednisone
Sensitive
:
A1
docetaxel + prednisone
Sensitive: A1 - Approval
docetaxel + prednisone
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
abiraterone acetate
Sensitive: A1 - Approval
abiraterone acetate
Sensitive
:
A1
abiraterone acetate
Sensitive: A1 - Approval
abiraterone acetate
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
degarelix
Sensitive: A1 - Approval
degarelix
Sensitive
:
A1
degarelix
Sensitive: A1 - Approval
degarelix
Sensitive
:
A1
ATM mutation
Prostate Cancer
ATM mutation
Prostate Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA1 mutation
Prostate Cancer
BRCA1 mutation
Prostate Cancer
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
BRCA2 mutation
Prostate Cancer
BRCA2 mutation
Prostate Cancer
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
HRD
Prostate Cancer
HRD
Prostate Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
zoledronic acid
Sensitive: A1 - Approval
zoledronic acid
Sensitive
:
A1
zoledronic acid
Sensitive: A1 - Approval
zoledronic acid
Sensitive
:
A1
FOLH1 positive
Prostate Cancer
FOLH1 positive
Prostate Cancer
lutetium Lu 177 vipivotide tetraxetan
Sensitive: A1 - Approval
lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
A1
lutetium Lu 177 vipivotide tetraxetan
Sensitive: A1 - Approval
lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
leuprolide mesylate injectable suspension
Sensitive: A1 - Approval
leuprolide mesylate injectable suspension
Sensitive
:
A1
leuprolide mesylate injectable suspension
Sensitive: A1 - Approval
leuprolide mesylate injectable suspension
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
MSI-H/dMMR
Prostate Cancer
MSI-H/dMMR
Prostate Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
mitoxantrone
Sensitive: A2 - Guideline
mitoxantrone
Sensitive
:
A2
mitoxantrone
Sensitive: A2 - Guideline
mitoxantrone
Sensitive
:
A2
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
etoposide IV
Sensitive: A2 - Guideline
etoposide IV
Sensitive
:
A2
etoposide IV
Sensitive: A2 - Guideline
etoposide IV
Sensitive
:
A2
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
atezolizumab
Sensitive: A2 - Guideline
atezolizumab
Sensitive
:
A2
atezolizumab
Sensitive: A2 - Guideline
atezolizumab
Sensitive
:
A2
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
docetaxel
Sensitive: A2 - Guideline
docetaxel
Sensitive
:
A2
docetaxel
Sensitive: A2 - Guideline
docetaxel
Sensitive
:
A2
CDK12 mutation
Prostate Cancer
CDK12 mutation
Prostate Cancer
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
PALB2 mutation
Prostate Cancer
PALB2 mutation
Prostate Cancer
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
CHEK2 mutation
Prostate Cancer
CHEK2 mutation
Prostate Cancer
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
CHEK1 mutation
Prostate Cancer
CHEK1 mutation
Prostate Cancer
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
AR splice variant 7
Prostate Cancer
AR splice variant 7
Prostate Cancer
abiraterone acetate
Resistant: A2 - Guideline
abiraterone acetate
Resistant
:
A2
abiraterone acetate
Resistant: A2 - Guideline
abiraterone acetate
Resistant
:
A2
AR splice variant 7
Prostate Cancer
AR splice variant 7
Prostate Cancer
enzalutamide capsule
Resistant: A2 - Guideline
enzalutamide capsule
Resistant
:
A2
enzalutamide capsule
Resistant: A2 - Guideline
enzalutamide capsule
Resistant
:
A2
RAD51B mutation
Prostate Cancer
RAD51B mutation
Prostate Cancer
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
RAD51C mutation
Prostate Cancer
RAD51C mutation
Prostate Cancer
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
RAD51D mutation
Prostate Cancer
RAD51D mutation
Prostate Cancer
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login